Conference Coverage

Close monitoring of psoriasis patients can delay PsA onset


 

EXPERT ANALYSIS FROM SDEF WOMEN'S & PEDIATRIC DERMATOLOGY SEMINAR

NEWPORT BEACH, CALIF. – A patient with psoriasis can develop crippling psoriatic arthritis (PsA) within 5 to 10 years of diagnosis, but monitoring patients for signs of trouble can help prevent the onset of PsA, according to Alan Menter, MD.

Even a simple foot examination can make a huge difference, noted Dr. Menter, chief of the division of dermatology and director of the Psoriasis Research Institute at Baylor University Medical Center, Dallas. “At every visit, you and I should be looking for early signs of joint disease,” he said at the Skin Disease Education Foundation’s Women’s & Pediatric Dermatology Seminar. “We should not let these patients develop any joint disease because we have drugs that can prevent joint destruction.”

Dr. Alan Menter

Estimates regarding the proportion of psoriasis patients who have PsA vary widely. The International Federation of Psoriasis Associations estimates that 30%-50% of people with psoriasis have PsA, while the Centers for Disease Control and Prevention estimates that 10%-20% of psoriasis patients eventually develop PsA. A study published in 2005 cited estimates ranging from 6% to 42% (Ann Rheum Dis. 2005;64:ii14-ii17).

Dr. Menter pointed out that PsA is a disease that is distinct from psoriasis. “It’s linked to psoriasis, but genetically, there are differences,” he said, “and immunologically, what goes on in skin is not identical.”

He provided the following pearls regarding diagnosing PsA:

• Be on the lookout for “sausage fingers” and “sausage toes,” both signs of PsA. “You and I are very visual people, and we can see a swollen toe or finger very easily,” Dr. Menter said. “I take the shoes off every psoriasis patient at every visit and run my thumb and index finger down the Achilles. I look for a swollen Achilles – classic enthesitis.” In some cases, swollen big toes in psoriasis patients may be misdiagnosed as gout instead of PsA, he noted.

• Ask patients about how their joints feel when they wake up in the morning: Do they have swelling and tenderness? “That’s an early marker of psoriatic arthritis disease,” Dr. Menter said. In contrast, in a patient with osteoarthritis, “the more they use their joints, the worse it gets.”

• The severity of psoriasis has nothing to do with the severity of PsA. “You can have 50% of the body covered with psoriasis but no arthritis,” he said. “Or you can have someone with one patch of psoriasis on the scalp with devastating joint disease.”

• Be aware that there are five PsA subtypes that can occur in combination with each other:

1. Dactylitis. This is the form that causes the “sausage digit.”

2. Asymmetric oligoarthritis. This is the type most commonly seen on presentation, when there are few joints affected.

3. Symmetric arthritis. This form is more common in females and difficult to differentiate from rheumatoid arthritis.

4. Distal interphalangeal joint arthritis. This type is often linked to dactylitis and nail dystrophy.

5. Arthritis mutilans. This is more common in females, linked to long disease duration, and present in an estimated 5% of cases.

Dr. Menter suggested that dermatologists refer suspected cases of PsA to a rheumatologist. Since patients may have to wait 6-10 weeks for an appointment, he recommended that dermatologists consider NSAIDs, such as the over-the-counter naproxen and prescription meloxicam and celecoxib in the meantime. Dermatologists may also consider bringing up the use of methotrexate and biologics, he said.

Dr. Menter disclosed relationships with multiple pharmaceutical companies, including AbbVie, Allergan, Amgen, Boehringer Ingelheim, Eli Lilly, Merck, Novartis, and Pfizer.

SDEF and this news organization are owned by Frontline Medical Communications.

Recommended Reading

Presenting Treatment Safety Data: Subjective Interpretations of Objective Information
MDedge Dermatology
Debunking Psoriasis Myths: Does UVB Phototherapy Cause Skin Cancer?
MDedge Dermatology
Birth outcomes unaffected by paternal immunosuppressive therapy
MDedge Dermatology
Guselkumab achieves highest-ever response rates in psoriasis
MDedge Dermatology
Scalp Psoriasis: Weighing Treatment Options
MDedge Dermatology
Surgical Risks From Systemic Psoriasis Therapies
MDedge Dermatology
Secukinumab for psoriasis at 4 years: undiminished efficacy and safety
MDedge Dermatology
Tildrakizumab for psoriasis scores high marks in phase III
MDedge Dermatology
Erratum
MDedge Dermatology
PsA bone loss measurement: A surrogate for radiographic progression?
MDedge Dermatology